B VAISSE CHU TIMONE MARSEILLE Que deviennent les bêtabloquants dans lHTA aujourd'hui ?

B VAISSE CHU TIMONE MARSEILLE Que deviennent les btabloquants dans lHTA aujourd'hui ?

LES BTABLOQUANTS DANS LHTA : les Mta Analyses

Effet de la baisse de PA sur les vnements cardiovasculaires majeurs Mtanalyse des Blood Pressure Lowering Treatment Trialists THE LANCET Vol 362 November 8, 2003

Should blockers remain first choice in the treatment of primary hypertension? A meta-analysis Beta Blockers versus Other Drugs Lindholm Lancet 2005; 366: 154553

EVALUATION DE LEFFICACITE DES BETA BLOQUANTS DANS LHTA : SUJETS < 60 ANS Khan Mc Alister CMAJ 2006;174(12):1737-42 Mortalit, AVC, IDM

EVALUATION DE LEFFICACITE DES BETA BLOQUANTS DANS LHTA : SUJETS > 60 ANS Khan Mc Alister CMAJ 2006;174(12):1737-42 Mortalit, AVC, IDM

Relative risk estimates of coronary heart disease events and stroke in single drug blood pressure difference trials according to class of drug M R Law BMJ 2009;338;b1665

Relative risk estimates of coronary heart disease events in single drug blood pressure difference trials according to drug ( blockers or other), presence of CHD, and for blockers according to acute myocardial infarction on entry. M R Law BMJ 2009;338;b1665

Relative risk estimates of coronary heart disease events and stroke in 46 drug comparison trials comparing each of the five classes of blood pressure lowering drug with any other class of drug M R Law BMJ 2009;338;b1665

LES BTABLOQUANTS DANS LHTA : les Grandes Etudes

0 2 4 6 8 10 12 14 16 Proportion of patients with first event (%) Intention-to-Treat Losartan Atenolol LIFE: Primary Composite Endpoint Study Month0612182430364248546066 Losartan (n)46054524446043924312424741894112404738971889901 Atenolol (n)45884494441443494289420541354066399238211854876 Adjusted Risk Reduction 130%, p=0021 Unadjusted Risk Reduction 146%, p=0009 B Dahlof et al. Lancet 2002;359:995-1003

LIFE : prvention des AVC en fonction de lge Kizer ; Hypertension. 2005;45:46-52

Losartan (%) Atenolol (%) p-value Losartan (%) Atenolol (%) p-value Angioedema6(01%)11(02%)0237 Bradycardia66(1%)391(9%)

ASCOT : vnements indsirables

B VAISSE CHU TIMONE MARSEILLE Que deviennent les bêtabloquants dans lHTA aujourd'hui ?

Documents

Transcript of B VAISSE CHU TIMONE MARSEILLE Que deviennent les bêtabloquants dans lHTA aujourd'hui ?